Prima completes recruitment for phase 2a ovarian cancer trial

By Lisa Kerner

Erie, Pa., Feb. 23 - Prima Biomed Ltd. said it has completed recruitment for its phase 2a clinical trial of its CancerVac technology for ovarian cancer.

"Closing patient recruitment is a crucial point in the clinical trial process, especially as recruitment was completed within the forecast timeframe," Prima chief executive officer Marcus Clark said in a company news release.

"Closing recruitment also provides us with a greater ability to forecast the finish of the treatment component of the trial and reduces cash burn for the company."

In the event of positive trial results, Prima said it plans a pivotal study in ovarian cancer and the eventual launch of a product in Australia, officials said.

Prima's partner Biomira, Inc. has the right to in-license Prima's CancerVac cell-based therapy.

CancerVac stimulates a patient's immune system to attack cancer cells, targeting a protein called Mucin-1, commonly found in large quantities on many kinds of cancer.

Prima has exclusive worldwide license to Mucin-1 from Biomira for use in its dedritic cell therapy for the treatment of cancer. Biomira has an option to secure commercialization rights for the technology worldwide, except for Australia and New Zealand.

Prima, a Melbourne, Australia-based biotechnology company, develops technologies in the fields of immunology and cancer immunotherapy.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.